| Tender Details | ||||||||
|
||||||||
| Deadline * | ||||||||
|
||||||||
| Client Address | ||||||||
|
||||||||
| More Information | ||||||||
| Know More | ||||||||
Similar Tenders
- Ref No: 2942305
- Location: Germany
Conclusion Of A Non Exclusive Framework Contract For Structural Testing According To Din 1076 In The Open House Procedure Of The East Branch
- Deadline: 31 Dec 2025
- Ref No: 3019900
- Location: Great Britain
Education Learning Improvement Services Open Framework
- Deadline: 31 Aug 2026
- Ref No: 3020010
- Location: Great Britain
Education Learning Improvement Services Open Framework
- Deadline: 31 Aug 2026
- Ref No: 3038815
- Location: Great Britain
Education Learning Improvement Services Open Framework
- Deadline: 31 Aug 2026
- Ref No: 3060173
- Location: Germany
Open Framework Agreement On Drug Discounts In Accordance With Section 130A Paragraph 8 Sgb V With The Possibility Of Joining At Any Time So Called Ap
- Deadline: 05 Jan 2026
- Ref No: 3087513
- Location: Germany
Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possib
- Deadline: 31 Dec 2026
- Ref No: 3135521
- Location: Netherlands
Open House Demand Dependent Wmo Transport
- Deadline: 01 Mar 2027
- Ref No: 3135895
- Location: Netherlands
Open House Job Coaching And Work Paths For The Target Group Of People With Disabilities
- Deadline: 01 Jun 2026
- Ref No: 3147164
- Location: Lithunia
Construction Work Technology Project Preparation And Demolition Works
- Deadline: 12 Feb 2034
- Ref No: 3236065
- Location: Great Britain
Dynamic Purchasing System Dps For Send Independent School Places
- Deadline: 31 Mar 2027
- Ref No: 3244470
- Location: Germany
Open House Drug Discount Agreements Vilanterol And Fluticasone Furoate Atc R03Ak10
- Deadline: 05 Jan 2026
- Ref No: 3245422
- Location: Germany
Open House Drug Discount Agreements Betahistin Atc N07Ca01
- Deadline: 05 Jan 2026
- Ref No: 3245472
- Location: Germany
Open House Drug Discount Agreements Adalimumab Atc L04Ab04
- Deadline: 05 Jan 2026